Emerging in the landscape of obesity therapy, retatrutide is a different strategy. Unlike many current medications, retatrutide works as a double agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) sensors. This simultaneous activation fosters several advantageous effects, lik